Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 31 January 2014 | By Alexander Gaffney, RAC,
Despite its name, Mini-Sentinel, the US Food and Drug Administration's (FDA) ambitious attempt at creating an active surveillance system, isn't so miniature. In fact, according to data released by the project this week, it's positively massive.
Before we dig into those numbers, some background information is in order.
Mini-Sentinel was created in 2008 as an effort to create a nationwide system to track products regulated by FDA after their approval. With the Food and Drug Administration Amendments Act (FDAAA) placing a far greater emphasis on post-approval requirements for drugs (instead of requiring all data to be submitted prior to approval), regulators and legislators realized FDA needed a way of keeping better track of adverse events to inform their ongoing assessments of product safety.
FDAAA called for the creation of the Mini-Sentinel system, and in 2010 FDA partnered with the Brookings Institute to bring together 21 different health care system providers capable of providing Mini-Sentinel with a constant stream of data and advice.
While only some of those partners provide FDA with data, those that do provide it with a ton.
Just how much data was on display in a report released by Mini-Sentinel this week reviewing the data obtained through the first three years of Sentinel's operation.
As of July 2012, the Mini-Sentinel System's Distributed Database (MSDD) includes information on 160 million individuals, 3.5 billion medication dispensings-more than 45 million per month-and 3.8 billion unique medical encounters.
For reference, the entire population of the United States was just 314 million in 2012, meaning the Mini-Sentinel database contained data on more than half the United States.
Where the system gets it data from varies. Nearly half, or 59.4 million unique members, are from a single source, while two others respectively contributed 31.7 and 32.7 million members to the database. Most other contributions were smaller, like the 400,000 patients contributed by yet another source. Looking at the list of Sentinel contributors, this makes sense. Some of the contributors are massive healthcare systems like Kaiser Permanente, while others are independent medical centers like the Vanderbilt University Medical Center.
But more than just the quantity of the data is the quality of the data. Mini-Sentinel's summary report notes that the longitudinal data they have on some patients allows them to track their health over a period of more than 10 years, and half the database for more than one year. That data is extremely useful for regulators because some drugs, such as those for chronic conditions, may have adverse events that only become apparent over a long time.
And while the data it receives is by no means perfect or complete, it has allowed the Mini-Sentinel group, which exists independently of FDA, to provide the agency with key information on the safety of products far more quickly than the agency could do by itself in the past.
"Mini-Sentinel is building the capacity to respond to many of FDA's safety questions within days or weeks," the group wrote on its website.
In other words, thanks to big data, the only thing "mini" about the Sentinel system may wind up being the waiting time between regulators asking a question and receiving an answer.
Mini-Sentinel Report
Tags: Mini-Sentinel
Regulatory Focus newsletters
All the biggest regulatory news and happenings.